Deutsche Bank Ag\ Voyager Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$245 Billion
Q1 2025

A detailed history of Deutsche Bank Ag\ transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 36,542 shares of VYGR stock, worth $107,433. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,542

Previous 42,470 13.96%

Holding current value

$107,433

Previous $240,000 48.75%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$3.38 - $6.04 $20,036 - $35,805	-5,928 Reduced 13.96%	36,542 $123,000
Q4 2024 Feb 14, 2025	SELL	$5.27 - $8.07 $189,182 - $289,696	-35,898 Reduced 45.81%	42,470 $240,000
Q3 2024 Jun 26, 2025	BUY	$5.77 - $9.27 $241,336 - $387,727	41,826 Added 114.46%	78,368 $458,000
Q3 2024 Nov 13, 2024	BUY	$5.77 - $9.27 $44,544 - $71,564	7,720 Added 10.93%	78,368 $458,000
Q2 2024 Jun 12, 2025	BUY	$7.42 - $10.54 $253,066 - $359,477	34,106 Added 93.33%	70,648 $558,000
Q2 2024 Aug 14, 2024	SELL	$7.42 - $10.54 $9,341 - $13,269	-1,259 Reduced 1.75%	70,648 $558,000
Q1 2024 Jun 02, 2025	BUY	$7.15 - $10.84 $252,859 - $383,356	35,365 Added 96.78%	71,907 $669,000
Q1 2024 May 15, 2024	BUY	$7.15 - $10.84 $43,765 - $66,351	6,121 Added 9.3%	71,907 $669,000
Q4 2023 Feb 14, 2024	BUY	$6.28 - $8.81 $5,991 - $8,404	954 Added 1.47%	65,786 $555,000
Q3 2023 Nov 09, 2023	SELL	$7.55 - $11.25 $23,737 - $35,370	-3,144 Reduced 4.63%	64,832 $502,000
Q2 2023 Aug 14, 2023	BUY	$6.94 - $13.99 $99,075 - $199,721	14,276 Added 26.58%	67,976 $778,000
Q1 2023 May 15, 2023	SELL	$6.0 - $10.78 $7,800 - $14,014	-1,300 Reduced 2.36%	53,700 $414,000
Q2 2022 Aug 11, 2022	BUY	$4.82 - $10.09 $265,100 - $554,950	55,000 New	55,000 $325,000
Q3 2021 Nov 04, 2021	SELL	$2.63 - $4.12 $1,659 - $2,599	-631 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$3.94 - $5.44 $104,634 - $144,470	-26,557 Reduced 97.68%	631 $3,000
Q1 2021 May 13, 2021	SELL	$4.61 - $9.04 $112,613 - $220,829	-24,428 Reduced 47.33%	27,188 $128,000
Q4 2020 Feb 16, 2021	SELL	$7.15 - $12.28 $224,381 - $385,370	-31,382 Reduced 37.81%	51,616 $369,000
Q3 2020 Nov 12, 2020	BUY	$10.01 - $13.75 $311,871 - $428,395	31,156 Added 60.1%	82,998 $886,000
Q2 2020 Aug 13, 2020	BUY	$8.05 - $14.21 $341,432 - $602,702	42,414 Added 449.87%	51,842 $654,000
Q1 2020 May 14, 2020	SELL	$6.8 - $14.66 $222,026 - $478,663	-32,651 Reduced 77.59%	9,428 $86,000
Q4 2019 Feb 14, 2020	BUY	$12.82 - $16.85 $394,009 - $517,867	30,734 Added 270.9%	42,079 $586,000
Q3 2019 Nov 14, 2019	SELL	$16.31 - $28.29 $109,391 - $189,741	-6,707 Reduced 37.15%	11,345 $194,000
Q2 2019 Aug 14, 2019	SELL	$19.18 - $27.88 $130,750 - $190,057	-6,817 Reduced 27.41%	18,052 $490,000
Q1 2019 May 15, 2019	SELL	$8.0 - $19.66 $970,912 - $2.39 Million	-121,364 Reduced 82.99%	24,869 $474,000
Q4 2018 Feb 14, 2019	BUY	$8.59 - $18.05 $58,729 - $123,407	6,837 Added 4.9%	146,233 $1.37 Million
Q3 2018 Dec 21, 2021	BUY	$17.11 - $21.74 $1.11 Million - $1.41 Million	64,899 Added 87.12%	139,396 $2.64 Million
Q3 2018 Nov 14, 2018	BUY	$17.11 - $21.74 $396,096 - $503,280	23,150 Added 45.09%	74,497 $1.41 Million
Q2 2018 Apr 21, 2020	BUY	$16.76 - $23.92 $200,097 - $285,580	11,939 Added 30.3%	51,347 $1 Million
Q2 2018 Aug 14, 2018	SELL	$16.76 - $23.92 $2.53 Million - $3.61 Million	-150,732 Reduced 79.27%	39,408 $769,000
Q1 2018 Oct 18, 2019	BUY	$16.16 - $31.31 $649,809 - $1.26 Million	40,211 Added 26.82%	190,140 $3.57 Million
Q1 2018 May 15, 2018	BUY	$16.16 - $31.31 $1.78 Million - $3.45 Million	110,333 Added 278.65%	149,929 $2.82 Million
Q4 2017 Feb 14, 2018	BUY	$12.26 - $25.88 $319,495 - $674,432	26,060 Added 192.52%	39,596 $655,000
Q3 2017 Nov 14, 2017	BUY	$8.37 - $20.59 $113,296 - $278,706	13,536	13,536 $278,000

Others Institutions Holding VYGR

# of Institutions

121

Shares Held

34.6M

Call Options Held

12.9K

Put Options Held

37.7K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $114M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account